Furthermore, targeting the ligand for PD-1, PD-L1, on tumor cells with Atezolizumab is currently under investigation in combination with NY-ESO-1 pulsed DC vaccination in patients with sarcoma (NCT02609984, Table 3), and in combination with the DEC-205/NY-ESO-1 fusion protein (CDX-1401) vaccine and the demethylation agent guadecitabine in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer (NCT03206047, Table 3). Here, PDCD1 is linked to neoplasm.